ArticleThe Journal of international medical research2020
Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study.
Article in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Time-dependent improvement of quality of life with teriparatide or alendronate therapy: a JOINT-05 sub-analysis.Journal of bone and mineral metabolism · 2025Trial
- Health-related quality of life and influencing factors in osteoporosis patients: A cross-sectional study based on the EQ-5D-3L Scale in China.Turkish journal of physical medicine and rehabilitation · 2026Article
- Correlation of serum pentraxin 3 expression with disease severity and its prognostic value in postmenopausal osteoporosis.BMC musculoskeletal disorders · 2025Article
- Therapeutic advantage of teriparatide in very elderly patients with proximal femoral fractures: a functional and BMD analysis.BMC musculoskeletal disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo evaluate the effect of teriparatide on life quality in patients with postmenopausal osteoporosis.
methodsPatients treated from January 2014 to December 2016 were retrospectively included. Patients were divided into two groups according the treatment received. Those in the teriparatide treatment group were followed up for 24 months, and patients in the control group received calcium supplements and vitamin D. Scores for back pain using a visual analog scale (VAS) and score of the Oswestry Disability Index (ODI) and 36-item Short Form Health Survey of life quality (SF-36) were evaluated at 3, 6, 12, and 24 months and compared between the groups.
resultsIn total, 126 patients were included in the teriparatide treatment group and 127 in the control group. There were no significant differences between the groups concerning body mass index, bone density, VAS back pain score, ODI, and SF-36 life quality scores at baseline. At 3, 6, 12, and 24 months' follow-up, VAS scores were significantly lower in the treatment group than in controls; ODI and SF-36 scores were significantly higher in the treatment group than in the control group.
conclusionTeriparatide can significantly decrease pain and increase mobility and life quality in patients with postmenopausal osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.